Sun Pharmaceutical To Acquire Ranbaxy For $3.2B

India's Sun Pharmaceutical Industries announced its plans to buy Ranbaxy Laboratories from Japan's Daiichi Sankyo Co in a $3.2 billion all-share deal. Ranbaxy shareholders will receive 0.8 of a Sun Pharma share for every Ranbaxy share. The deal price represents an 18% premium to Ranbaxy's 30-day volume-weighted average stock price.